Sugi Predict

Sugi Predict / Compounds / SCHEMBL1327631

SCHEMBL1327631

SCHEMBL1327631

Cc1nc(-c2ccccc2)sc1C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 8/20 1.00
▸ RAB9A P51151 6/20 0.78
▸ KDM4E B2RXH2 4/20 0.78
▸ GAA P10253 2/20 0.78
▸ ALDH1A1 P00352 6/20 0.73
▸ NPC1 O15118 4/20 0.73
▸ HPGD P15428 2/20 0.73
▸ NPSR1 Q6W5P4 1/20 0.73
▸ POLB P06746 1/20 0.73
▸ MAPT P10636 4/20 0.69
▸ KMT2A Q03164 4/20 0.65
▸ LMNA P02545 1/20 0.64
▸ ATM Q13315 1/20 0.64
▸ MEN1 O00255 2/20 0.62
▸ L3MBTL1 Q9Y468 2/20 0.62
▸ CNR1 P21554 1/20 0.59
▸ TARBP2 Q15633 1/20 0.59
▸ TDP1 Q9NUW8 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL289112 0.97 SMN1; SMN2 (0.93) SMN1; SMN2RAB9AKDM4EGAAALDH1A1
SCHEMBL289554 0.92 SMN1; SMN2 (0.85) SMN1; SMN2RAB9AKDM4EGAAALDH1A1
SCHEMBL892234 0.88 RAB9A (1.00) SMN1; SMN2RAB9AKDM4EGAAALDH1A1
SCHEMBL851866 0.88 SMN1; SMN2 (0.78) SMN1; SMN2RAB9AKDM4EGAAALDH1A1
SCHEMBL8867115 0.88 SMN1; SMN2 (0.77) SMN1; SMN2RAB9AKDM4EGAAALDH1A1
SCHEMBL892990 0.86 SMN1; SMN2 (0.76) SMN1; SMN2RAB9AKDM4EGAAALDH1A1
SCHEMBL8867051 0.86 RAB9A (0.79) SMN1; SMN2RAB9AKDM4EGAAALDH1A1
SCHEMBL3328924 0.86 SMN1; SMN2 (0.76) SMN1; SMN2RAB9AKDM4EGAAALDH1A1
SCHEMBL2011167 0.86 RAB9A (0.79) SMN1; SMN2RAB9AKDM4EGAAALDH1A1
SCHEMBL4243016 0.86 SMN1; SMN2 (0.76) SMN1; SMN2RAB9AKDM4EGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107365989-A A kind of metal surface treating method and its obtained metal protective film 东莞市富默克化工有限公司 2017-11-21 — — CN claimed
CN-101384544-B Substituted cyclohexylmethyl derivatives GRUENENTHAL GMBH 2014-01-22 — — CN claimed
EP-1963313-B1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) MADRIGAL PHARMACEUTICALS INC (US) 2012-11-14 — — EP claimed
US-8058475-B2 Substituted cyclohexylmethyl compounds GRUENENTHAL GMBH (DE) 2011-11-15 — — US claimed
EP-1989174-B1 SUBSTITUTED CYCLOHEXYLMETHYL DERIVATIVES GRUENENTHAL GMBH (DE) 2011-08-03 — — EP claimed
EP-2197875-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Via Pharmaceuticals, Inc. (US) 2010-06-23 — — EP claimed
US-20090286833-A1 Substituted Cyclohexylmethyl Compounds GRUENENTHAL GMBH (DE) 2009-11-19 — — US claimed
WO-2009037222-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2009-03-26 — — WO claimed
CN-101384544-A Substituted cyclohexylmethyl derivatives GRUENENTHAL GMBH (DE) 2009-03-11 — — CN claimed
CN-101316844-A Inhibitors of diacylglycerol acyltransferase (DGAT) HOFFMANN LA ROCHE (CH) 2008-12-03 — — CN claimed
EP-1963313-A2 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) F.HOFFMANN-LA ROCHE AG (CH) 2008-09-03 — — EP claimed
WO-2007060140-A2 INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE (DGAT) F. HOFFMANN-LA ROCHE AG (CH) 2007-05-31 — — WO claimed
US-20070049618-A1 Isoindole-imide compounds and compositions comprising and methods of using the same CELGENE CORPORATION 2007-03-01 — — US claimed
US-20060052365-A1 Protease inhibitors SMITHKLINE BEECHAM CORPORATION 2006-03-09 — — US claimed
JP-2006505526-A — — 2006-02-16 — — JP claimed
EP-1539178-A2 PROTEASE INHIBITORS SmithKline Beecham Corporation (US) 2005-06-15 — — EP claimed
WO-2004017911-A2 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-03-04 — — WO claimed
CN-112752837-B Natural killer cells 帝国理工学院创新有限公司 2026-05-15 — — CN disclosed
EP-0513379-B1 2-ARYLTHIAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME TEIJIN LTD (JP) 1996-09-11 — — EP disclosed
EP-0513379-A1 2-ARYLTHIAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME TEIJIN LIMITED (JP) 1992-11-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286833-A1 Substituted Cyclohexylmethyl Compounds CNR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R SMN1; SMN2 1867/4885RAB9A 905/4885KDM4E 940/4885
US-20060052365-A1 Protease inhibitors CTSS, CTSE, CMA1 SMN1; SMN2 4826/4885RAB9A 897/4885KDM4E 2095/4885
US-20070049618-A1 Isoindole-imide compounds and compositions comprising and methods of using the same SI, CYP3A5, CYP2D6 SMN1; SMN2 1271/4885RAB9A 914/4885KDM4E 1501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.